Sinorda Pharmaceutical

Keyword:

Products News Download

Linaprazan glurate capsules

Gastroesophageal reflux disease (GERD) is a common digestive disorder characterized by the backflow of stomach contents—such as gastric acid and bile—into the esophagus, leading to uncomfortable symptoms and/or complications.

Keyword:

Sinorda Pharmaceutical

Latest News

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

The 2025 Nobel Prize in Physiology or Medicine Announced

Sinorda Pharmaceutical Named to the "2025 China's Top 101 Innovative Pharmaceutical Companies" List

Email: info1@sinorda.com

Zip code: 550018

Address: Guizhou Province Guiyang City National High-tech Zone West R & D Base

Consultation Hotline

0851-84847104

Business license

Label | Website construction: www.300.cn-GuiYang